The U.S. drugmaker will build a new campus in New Jersey for about 2,500 that it promises will pump up "collaboration, creativity and innovation," much as Biogen Idec, Novartis and others have done before it.
Last week the FDA cracked down hard on low-T therapies. Its expert panel voted to advise the agency to restrict the use of such drugs for a specific medical need.
After two false starts in the summer, drug delivery company Microlin Bio is once again withdrawing its planned IPO due to unfavorable market conditions. It had hoped to raise $28 million by offering 5.1 million shares on the Nasdaq priced between $4.50 and $5.50, Renaissance Capital reports.
Lipocine is touting positive late-stage results for its testosterone replacement pill, gearing up for intense FDA scrutiny amid a sea change in how the regulator looks at so-called low-T treatments.
A Purdue University team has created a new chip that promises to help test how cancer-killing nanoparticles react in a tumor environment. Because different nanoparticles perform vastly different functions in drug delivery, it's important to determine early on what kind of effect they will have on a tumor and what it would take to improve their outcome.
Titan Pharmaceuticals said yesterday that the Phase III study of its Probuphine subdermal implant for the treatment of opioid dependence is now halfway to full enrollment and on track to conclude by mid-2015, giving the company a second crack at FDA approval.
As researchers and investors toast renewed optimism for a new generation of gene therapies, biotech bellwether Biogen Idec is deepening its commitment to the space, another sign of life for the resurgent field.
Lonely, depressed, stressed? There's a smartphone app that can read your mood like a book. At Dartmouth, student researchers developed and tested StudentLife, an app that can detect depression and stress levels.
Sequenom, facing a crowd of rivals in the prenatal diagnostics space, is heralding a massive amount of new postmarketing data as proof of accuracy and sensitivity for its signature test.
BBK Worldwide has raised $3 million to finance an expansion of its suite of eClinical software.